Multiple other studies have demonstrated that anti-TNF-α agents improve FMD in RA patients who are refractory to conventional disease modifying anti-rheumatic drugs (DMARD) therapy [112,113,114,115,116,117]. The gene discussed is TNF; the disease is rheumatoid arthritis.